MedTrace Logo

A Study of ZSTK474 in Japanese Patients With Advanced Solid Malignancies

NCT01682473 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-07-06

No results posted yet for this study

Summary

To evaluate the safety (adverse events and dose-limiting toxicity) of daily oral doses of ZSTK474 in patients with advanced solid malignancies.

Conditions

  • Neoplasms

Interventions

DRUG

ZSTK474

Two arms, each with serial cohorts receiving escalating doses.

Sponsors & Collaborators

  • Zenyaku Kogyo Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Toshihiko Doi, MD, PhD · National Cancer Center Hospital East

  • Shunji Takahashi, MD · The Cancer Institute Hospital of JFCR

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-20
Primary Completion
2015-04-02
Completion
2015-04-20

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01682473 on ClinicalTrials.gov